The gene-silencing technology, developed by CSIRO, will be used on 14
US patients suffering from hepatitis C, in the hope it can fight off
If proved safe and effective, the treatment could allow doctors to directly place medication into a patient’s genes.
company Benitec Biopharma gained approval from the US Food and Drug
Administration for a trial of the technology, known as DNA Directed RNA
Interference. The trial will be run at Duke University and the
University of California over the next 18 months.